Ubie Announces Social Impact Framework, Shows Estimated Patient Life Expectancy Impact of 27,000 Years and Approximately $1BN
Ubie has taken the lead in implementing a new standard of measurement to evaluate health and economic impact for global digital health startups The framework uses the pharmaceutical industry's standard of Quality-Adjusted Life Years (QALY) to provide a widely-accepted and transparent impact measurement Preliminary results support the ability of Ubie's AI...
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 64Cu-SAR-bisPSMA for...
Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer
PALO ALTO, Calif., Aug. 22, 2024 /PRNewswire/ -- I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial using iPS cell-derived natural killer (iNK) cells for ovarian cancer immunotherapy....
Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
NANTONG and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-18, one of the company's lead saRNA product candidates. This designation follows the recent Rare Pediatric Disease Designation (RPDD) granted to RAG-18...
Ping An Reports Stable Operating Profit Attributable to Shareholders of the Parent Company and Interim Dividends, with a 6.8% YoY Increase in Net Profit
Life & Health NBV jumps 11.0% YoY, demonstrating significant positive results in high-quality business development HONG KONG and SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) today announced its 2024 interim results for the six month period ended 30 June 2024. In the...
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World’s First In Vivo Gene Editing Therapy for PH1
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene editing company dedicated to delivering lifelong cures, today announced a major milestone: the first patient has been dosed with YOLT-203, the company's cutting-edge in vivo genome editing candidate. This marks the commencement of an Investigator-Initiated Trial (IIT) and represents a global first in the application of in vivo gene...
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
MELBOURNE, Australia, Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated. H1 2024 financial highlights Total Group revenue of $364.0 million, an increase of 65% compared to H1 2023,...
Inaugural Process Innovation Asia Pacific to Drive Industry Transformation for South-East Asia’s Chemicals and Pharmaceuticals
SINGAPORE, Aug. 22, 2024 /PRNewswire/ -- Organised by Constellar, in partnership with DECHEMA Ausstellungs-GmbH (DECHEMA Exhibitions), the inaugural Process Innovation Asia Pacific - Powered by ACHEMA (PIA) will be held from 19 to 21 November 2024 at Singapore EXPO. The most comprehensive Process Technology show for South-East Asia, PIA 2024 will address...
Chen Institute and Science to Hold Innovative Conference in Shanghai Spotlighting Latest Developments in “Artificial Intelligence and Mental Health”
Registration is open for the Nov 7-8, Shanghai Meeting REDWOOD CITY, Calif., Aug. 22, 2024 /PRNewswire/ -- Today, the Tianqiao and Chrissy Chen Institute (the Chen Institute) and Science announced that they are holding the second of their annual conference series focused on Artificial Intelligence (AI) and Mental Health in Shanghai, November 7-8, 2024. The meeting is being co-hosted...
Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16
SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the launch of an Investigator-Initiated Clinical Trial (IIT) for a personalized mRNA cancer vaccine, EVM16, under the study EVM16CX01, at the Peking University Cancer Hospital and Fudan University's Cancer...
